Table 2 Distribution of women with ovarian carcinoma according to the percentage of matrix metalloproteinase-14 (MMP-14)-positive cells (visual) and positive area (digital image analysis) and standard prognostic factors
% MMP-14-positive cells, visual scoring (total n=160) | % MMP-14-positive area, digital image analysis, per quartile (total n=170) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
0 | 1–20 | 21–40 | >40 | P | 1st | 2nd | 3rd | 4th | P | |
n/55 (%) | n/45 (%) | n/42 (%) | n/18 (%) | n/43 (%) | n/42 (%) | n/43 (%) | n/42 (%) | |||
Age group (years) | ||||||||||
<50 | 7 (13) | 14 (31) | 10 (24) | 5 (28) | 0.3 | 10 (23) | 8 (19) | 6 (14) | 12 (29) | 0.2 |
50–59 | 19 (35) | 10 (22) | 12 (29) | 4 (22) | 13 (30) | 9 (21) | 15 (35) | 11 (26) | ||
60–69 | 16 (29) | 8 (18) | 14 (33) | 6 (33) | 7 (16) | 13 (31) | 11 (26) | 15 (36) | ||
≥70 | 13 (24) | 13 (29) | 16 (14) | 3 (17) | 13 (30) | 12 (29) | 11 (26) | 4 (10) | ||
FIGO stage | ||||||||||
I–II | 9 (16) | 9 (20) | 17 (41) | 12 (67) | <0.0001 | 8 (19) | 7 (17) | 12 (28) | 20 (48) | 0.005 |
III–IV | 46 (84) | 36 (80) | 25 (60) | 6 (33) | 35 (81) | 35 (83) | 31 (72) | 22 (52) | ||
Histology | ||||||||||
Serous | 46 (84) | 37 (82) | 20 (48) | 5 (28) | <0.0001 | 36 (84) | 36 (86) | 29 (67) | 17 (41) | <0.0001 |
Others | 9 (16) | 8 (18) | 22 (52) | 13 (72) | 7 (16) | 6 (14) | 14 (33) | 25 (60) | ||
Grade | ||||||||||
Low | 8 (15) | 6 (13) | 7 (17) | 4 (22) | 0.8 | 7 (16) | 6 (14) | 6 (14) | 9 (21) | 0.8 |
High | 47 (86) | 39 (87) | 35 (83) | 14 (78) | 36 (84) | 36 (86) | 37 (86) | 33 (79) | ||
Preoperative CA-125, quartiles (U/ml) | ||||||||||
0–151 | 6 (11) | 10 (22) | 11 (26) | 8 (44) | 0.02 | 8 (19) | 6 (14) | 5 (12) | 17 (41) | 0.02 |
152–441 | 17 (31) | 9 (20) | 10 (24) | 4 (22) | 10 (23) | 13 (31) | 12 (28) | 8 (19) | ||
442–1179 | 17 (31) | 12 (27) | 4 (10) | 5 (28) | 12 (28) | 15 (36) | 10 (23) | 5 (12) | ||
≥1180 | 15 (27) | 14 (31) | 17 (41) | 1 (6) | 13 (30) | 8 (19) | 16 (37) | 12 (29) | ||
